Drugs by condition
Drugs approved for melanoma
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
21
Still marketed, NDA or BLA
Drug classes
7
Novel drugs
15
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for melanoma.
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
- Opdivo Qvantig (Nivolumab, Hyaluronidase-Nvhy) · Bristol-Myers Squibb Accelerated approvalDec 27, 2024
- Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs) · Genentech INC Sep 12, 2024
- Hepzato (Melphalan Hydrochloride) · Delcath Systems INC OrphanAug 14, 2023
- Mekinist (Trametinib, Trametinib Dimethyl Sulfoxide) · Novartis Priority reviewOrphanMar 16, 2023
All approved drugs for melanoma, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Programmed Death Receptor-1 Blocking Antibody (5)
- Opdualag Nivolumab, Relatlimab-Rmbw · Bristol Myers Squibb · 2022
- Tecentriq Atezolizumab · Genentech INC · 2016
- Opdivo Nivolumab · Bristol Myers Squibb · 2014
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024
Endoglycosidase (2)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager (1)
- Kimmtrak Tebentafusp-Tebn · Immunocore LTD · 2022
Kinase Inhibitor (1)
- Zelboraf Vemurafenib · Hoffmann La Roche · 2011
CTLA-4-directed Blocking Antibody (1)
- Yervoy Ipilimumab · Bristol Myers Squibb · 2011
Lymphocyte Growth Factor (1)
- Proleukin Aldesleukin · Chiron · 1992
Class not listed in FDA's data (10)
- Braftovi Encorafenib · Array Biopharma INC · 2018
- Mektovi Binimetinib · Array Biopharma INC · 2018
- Cotellic Cobimetinib Fumarate · Genentech INC · 2015
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Lymphoseek Kit Technetium Tc-99m Tilmanocept · Cardinal Health 414 · 2013
- Hepzato Melphalan Hydrochloride · Delcath Systems INC · 2023
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- An-Sulfur Colloid Technetium Tc-99m Sulfur Colloid Kit · Sun Pharm Inds INC · 1978
Drugs in development for melanoma
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- DarovasertibIDE 196, LXS196Phase 35 trials
IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma
- ONC-392Gotistobart, BNT316Phase 35 trials
OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- EIK1001Phase 33 trials
Eikon Therapeutics · Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous)
- IO102-IO103Phase 33 trials
IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma
- ABP 206Phase 32 trials
Amgen · Melanoma
More on melanoma: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Colorectal cancer · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.